Bioxytran (OTCMKTS:BIXT) versus ALX Oncology (NASDAQ:ALXO) Financial Survey

Bioxytran (OTCMKTS:BIXT) and ALX Oncology (NASDAQ:ALXO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership and dividends.

Profitability

This table compares Bioxytran and ALX Oncology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bioxytran	N/A	N/A	-737.48%
ALX Oncology	N/A	-124.06%	-85.57%

Risk and Volatility

Bioxytran has a beta of 1.69, meaning that its stock price is 69% more volatile than the S&P 500. Comparatively, ALX Oncology has a beta of 0.44, meaning that its stock price is 56% less volatile than the S&P 500.

Institutional and Insider Ownership

98.0% of ALX Oncology shares are owned by institutional investors. 70.0% of Bioxytran shares are owned by company insiders. Comparatively, 21.0% of ALX Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Bioxytran and ALX Oncology, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioxytran	0	0	0	0	0.00
ALX Oncology	1	0	5	0	2.67

ALX Oncology has a consensus price target of $4.60, suggesting a potential upside of 125.49%. Given ALX Oncology’s stronger consensus rating and higher probable upside, analysts clearly believe ALX Oncology is more favorable than Bioxytran.

Valuation & Earnings

This table compares Bioxytran and ALX Oncology”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioxytran	N/A	N/A	-$2.12 million	($0.02)	-1.42
ALX Oncology	N/A	N/A	-$101.69 million	($1.49)	-1.37

Bioxytran is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks.

Summary

ALX Oncology beats Bioxytran on 6 of the 11 factors compared between the two stocks.

About Bioxytran

Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company’s lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was founded in 2008 and is headquartered in Needham, Massachusetts.

About ALX Oncology

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.